Cargando…
Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody
To explore stem-cell-targeted radioimmunotherapy with α-particles in acute myelogenous leukemia (AML), pharmacokinetics and dosimetry of the (211)At-labeled anti-C-X-C chemokine receptor type 4 monoclonal antibody ((211)At-CXCR4 mAb) were conducted using tumor xenografted mice. The biological half-l...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176675/ https://www.ncbi.nlm.nih.gov/pubmed/32321944 http://dx.doi.org/10.1038/s41598-020-63557-9 |
_version_ | 1783525055074926592 |
---|---|
author | Oriuchi, Noboru Aoki, Miho Ukon, Naoyuki Washiyama, Kohshin Tan, Chengbo Shimoyama, Saki Nishijima, Ken-ichi Takahashi, Kazuhiro Ito, Hiroshi Ikezoe, Takayuki Zhao, Songji |
author_facet | Oriuchi, Noboru Aoki, Miho Ukon, Naoyuki Washiyama, Kohshin Tan, Chengbo Shimoyama, Saki Nishijima, Ken-ichi Takahashi, Kazuhiro Ito, Hiroshi Ikezoe, Takayuki Zhao, Songji |
author_sort | Oriuchi, Noboru |
collection | PubMed |
description | To explore stem-cell-targeted radioimmunotherapy with α-particles in acute myelogenous leukemia (AML), pharmacokinetics and dosimetry of the (211)At-labeled anti-C-X-C chemokine receptor type 4 monoclonal antibody ((211)At-CXCR4 mAb) were conducted using tumor xenografted mice. The biological half-life of (211)At-CXCR4 mAb in blood was 15.0 h. The highest tumor uptake of 5.05%ID/g with the highest tumor-to-muscle ratio of 8.51 ± 6.14 was obtained at 6 h. Radiation dosimetry estimated with a human phantom showed absorbed doses of 0.512 mGy/MBq in the bone marrow, 0.287 mGy/MBq in the kidney, and <1 mGy/MBq in other major organs except bone. Sphere model analysis revealed 22.8 mGy/MBq in a tumor of 10 g; in this case, the tumor-to-bone marrow and tumor-to-kidney ratios were 44.5 and 79.4, respectively. The stem-cell-targeted α-particle therapy using (211)At-CXCR4 mAb for AML appears possible and requires further therapeutic studies. |
format | Online Article Text |
id | pubmed-7176675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-71766752020-04-27 Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody Oriuchi, Noboru Aoki, Miho Ukon, Naoyuki Washiyama, Kohshin Tan, Chengbo Shimoyama, Saki Nishijima, Ken-ichi Takahashi, Kazuhiro Ito, Hiroshi Ikezoe, Takayuki Zhao, Songji Sci Rep Article To explore stem-cell-targeted radioimmunotherapy with α-particles in acute myelogenous leukemia (AML), pharmacokinetics and dosimetry of the (211)At-labeled anti-C-X-C chemokine receptor type 4 monoclonal antibody ((211)At-CXCR4 mAb) were conducted using tumor xenografted mice. The biological half-life of (211)At-CXCR4 mAb in blood was 15.0 h. The highest tumor uptake of 5.05%ID/g with the highest tumor-to-muscle ratio of 8.51 ± 6.14 was obtained at 6 h. Radiation dosimetry estimated with a human phantom showed absorbed doses of 0.512 mGy/MBq in the bone marrow, 0.287 mGy/MBq in the kidney, and <1 mGy/MBq in other major organs except bone. Sphere model analysis revealed 22.8 mGy/MBq in a tumor of 10 g; in this case, the tumor-to-bone marrow and tumor-to-kidney ratios were 44.5 and 79.4, respectively. The stem-cell-targeted α-particle therapy using (211)At-CXCR4 mAb for AML appears possible and requires further therapeutic studies. Nature Publishing Group UK 2020-04-22 /pmc/articles/PMC7176675/ /pubmed/32321944 http://dx.doi.org/10.1038/s41598-020-63557-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Oriuchi, Noboru Aoki, Miho Ukon, Naoyuki Washiyama, Kohshin Tan, Chengbo Shimoyama, Saki Nishijima, Ken-ichi Takahashi, Kazuhiro Ito, Hiroshi Ikezoe, Takayuki Zhao, Songji Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody |
title | Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody |
title_full | Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody |
title_fullStr | Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody |
title_full_unstemmed | Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody |
title_short | Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody |
title_sort | possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)at-cxcr4 monoclonal antibody |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176675/ https://www.ncbi.nlm.nih.gov/pubmed/32321944 http://dx.doi.org/10.1038/s41598-020-63557-9 |
work_keys_str_mv | AT oriuchinoboru possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT aokimiho possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT ukonnaoyuki possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT washiyamakohshin possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT tanchengbo possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT shimoyamasaki possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT nishijimakenichi possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT takahashikazuhiro possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT itohiroshi possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT ikezoetakayuki possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody AT zhaosongji possibilityofcancerstemcelltargetedradioimmunotherapyforacutemyelogenousleukemiausing211atcxcr4monoclonalantibody |